AngioDynamics (ANGO)
Builds vascular and oncology devices around atherectomy, thrombectomy, ablation, and access lines.
Something off on this page? Send us feedback.
Sells Med Tech platforms such as Auryon, AngioVac/AlphaVac, and NanoKnife alongside Med Device lines for venous care, ports, access, and other oncology uses. Sales are concentrated in the United States, and the portfolio is being narrowed toward higher-focus vascular and oncology platforms.
Provides vascular and oncology devices through a Med Tech segment built around Auryon for peripheral atherectomy, AngioVac and AlphaVac for thrombus removal, and NanoKnife for ablation. The remaining Med Device lines cover venous products, ports, access tools, and other oncology devices.
Revenue is concentrated in the United States, with international sales a smaller part of the mix. The company's execution focus is shifting from a broader catheter and vascular-access base toward differentiated platforms after divestitures and discontinued product lines.
The business depends on hospital procedure demand, physician adoption of named platforms, regulatory clearance for device indications, and competition from larger medical-device companies across vascular, oncology, and access markets.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 15, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $14 | Target: $19 |
| Jul 15, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $18 | Target: $20 |
| Oct 3, 2025 | Canaccord Genuity | Reiterate | Rating: —Target: $17 | Target: $18 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, May 31, 2026Cash & short-term investments $53.9M · Total debt $0 · Total assets $267.2M · Shareholders' equity $170.8M
- Revenue
- $86.6M
- Operating income
- −$20.4M
- Net income
- −$11.4M
No dividends on record.
| Institutions | 92.79% | 38.35M shares | |
|---|---|---|---|
| 163 holders · as of Jun 30, 2026 | |||
| Insiders | 11.59% | 4.79M shares | |
| 14 holders · as of Jul 31, 2026 | |||
| Adds to | 104.38% | ||
41.33M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 104.38%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 9.20% | 3.80M | as of Jun 30, 2026 |
Point72 Asset Management, L.P.Institution | 7.41% | 3.06M | as of Jun 30, 2026 |
Systematic Financial Management LPInstitution | 6.39% | 2.64M | as of Jun 30, 2026 |
Kevin KotlerInsider | 5.86% | 2.42M | filed Feb 9, 2026 |
Victory Capital Management Inc.Institution | 5.36% | 2.21M | filed Feb 1, 2022 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 30, 2026 | Warren JR Nighan | officer: SVP Quality and Regulatory | −23,370 | $14.72 |
| Oct 21, 2025 | Lawrence T. Weiss | officer: SVP, Chief Legal Officer | +10,000 | $11.81 |
| Oct 13, 2025 | Stephen A. Trowbridge | officer: EVP and CFO | +890 | $11.16 |
| Oct 9, 2025 | James C. Clemmer | director, officer: President and CEO | +10,000 | $11.15 |
- Boston Scientific
Broadest overlap in PAD, thrombectomy, venous, and oncology tools
- Penumbra
Focused pressure in mechanical thrombectomy and PE/VTE clot removal
- Philips (ADR)
Laser and hybrid atherectomy overlap in PAD procedures
- Medtronic
PAD atherectomy and venous treatment overlap with vascular platforms
- Abbott
Peripheral artery disease portfolio overlaps Auryon and access devices
- BD
Major vascular access and implantable port competitor
- Merit Medical Systems
Interventional radiology peer across access, drainage, and dialysis
- Teleflex
Vascular access pressure through Arrow catheter and access lines
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| AngioDynamics | $15.60 | +1.19% | $637.3M | — | — | 2.0 | +8.1% |
| Boston Scientific | $44.73 | +2.31% | $64.98B | 17.8 | 13.6 | 3.1 | +7.5% |
| Penumbra | $319.19 | +0.13% | $12.56B | 78.3 | 57.6 | 8.3 | +14.9% |
| Philips (ADR) | $25.01 | +0.42% | $24.34B | 18.7 | 13.0 | 1.2 | −2.8% |
| Medtronic | $90.96 | −0.86% | $117.44B | 22.6 | 15.2 | 3.1 | +13.7% |
| Abbott | $104.21 | +1.19% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| BD | $182.91 | +1.22% | $49.79B | 54.4 | 13.8 | 2.4 | −9.6% |
| Merit Medical Systems | $87.30 | +2.12% | $5.10B | 35.3 | 20.0 | 3.2 | +9.5% |
| Teleflex | $124.30 | −0.40% | $5.52B | — | 13.4 | 2.1 | −27.0% |
| Median | 33.1 | 14.5 | 3.1 | +8.5% |